who is eligible for glp 1 ๐ข Two important dates patients interested in GLP-1 medications: โ July 1, 2026 โ Medicare GLP-1 Bridge Program begins for Medicare Part D beneficiaries. โ October 1, 2026 โ Zepbound GLP-1 Medications for Weight Loss
Description
Novo Nordisk has cut its full-year forecast three times in 2025 as GLP-1 growth rates decelerated sharply
Patients with statin intolerance should first consider evidence-based alternatives like ezetimibe, bempedoic acid, PCSK9 inhibitors, or inclisiran before considering GLP-1 therapy primarily for lipid management
The replacement of GLP-1 (737) Lys 34 with Arg causes a two-fold reduction in the EC 50
(Lilly) has a legal monopoly
Physicians use of the 5As in counseling obese patients: is the quality of counseling associated with patients motivation and intention to lose weight
IQVIA blog, August 2025: IQVIA blog, August 2025: [14] Oral obesity therapies: Holding the keys to the future
